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EmbolizationAbstract Aim: To evaluate the potential role, efficacy, and complications of endovascular man-
agement of postpartum hemorrhage induced by variable placental abnormalities.
Materials and methods: Ten patients with placental abnormalities underwent pelvic arterial
embolization in Assiut University Hospital, because of postpartum hemorrhage. Placental abnor-
malities were; retained placenta (n= 4), placenta accrete vera (n= 1), placenta increta (n= 2), pla-
centa percreta (n= 1), and choriocarcinoma (n= 2). Only three patients were embolized on
emergency bases, while the other 7 patients were scheduled for embolization.
Results: The mean hemoglobin level before embolization was 6 g/dL (range: 4.5–8 g/dL). Severe
coagulation disorders were present in one patient. Postembolization pelvic angiogram showed total
devascularization of the pathological arteries in 7(70%) patients, and subtotal devascularization in
3(30%) patients. The clinical success is 100%.
Conclusion: Whatever the placental disease, pelvic embolization with long-lasting embolizing
agents is very effective and safe treatment of associated postpartum hemorrhage.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Placental diseases that may cause postpartum hemorrhage
(PPH) include placenta accreta (PA), gestational trophoblastic
neoplasm (GTN), and retained placenta and products of con-
ception. PA has been defined as placental penetration into the
myometrium. Conventional extirpation management of PAcarries out high risk of severe hemorrhage with mortality rates
approaching 25% (1). If emergency hysterectomy was
performed, mortality rate might be reduced to 6% (1), but
the patient will lose her potential for future fertility. To reduce
mortality and morbidity and preserve the patient fertility, a
conservative method of management, leaving the uterus and
the placenta inside, was developed aiming at spontaneous
resorption of the placenta (2–4). Pelvic arterial embolization
has been shown to be effective in the treatment of PA induced
postpartum hemorrhage after extirpative or conservative man-
agement (5–10). Uterine hemorrhage might occur in women
with GTN, as the uterus is usually enlarged with hypervascular
and friable tumor inside. Traditionally, hysterectomy has been
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angiography and transcatheter embolization have become more
popular (11–13), because most of these tumors are chemosensi-
tive and usually cured without need for hysterectomy. Accord-
ingly, we report our experience involving 10 consecutive
patients with different placental diseases presented by postpar-
tum hemorrhage. We aimed to evaluate the potential role and
efficacy of pelvic embolization in the management of these
patients and to report any complications of this procedure.2. Patients and methods
This retrospective study did not require institutional review
board approval. Between January 2009 and September 2014,
ten patients with placental abnormalities underwent pelvic
arterial embolization in Assiut University Hospital, because
of postpartum hemorrhage. Their ages ranged from 20 to
38 years with mean age 27.4 years. All but two women were
referred from outside of our institution. Six patients presented
after normal vaginal delivery, and the other four patients pre-
sented after cesarean section (Table 1). When the ultrasound
examination showed intrauterine placenta without description
of the degree of myometrial invasion, we termed it ‘‘retained
placenta”. Prenatal diagnosis of placenta accreta occurred in
only one patient based on typical ultrasonographic and color
Doppler findings. The diagnosis of placenta accreta in the
other 4 patients occurred when total manual removal of the
placenta was impossible (n= 3), or when bleeding from the
implantation site started just after forced placental extirpation
(n= 1). Choriocarcinoma (n= 2) was diagnosed when the
beta-human chorionic gonadotrophin (B-HCG) was very high
and raised sequentially for 2 weeks.
In all patients pelvic ultrasonographic examination was the
first imaging modality to detect the cause of hemorrhage.
MRI was performed for patients with placenta accreta orTable 1 Types of abnormal placentation, mode of delivery and tim
Patient
no.
Age
(y)
Placentation Mode of delivery and
management
Time b
delivery
1 23 Retained portion Normal 4 days
2 28 Retained portion Normal 7 days
3 32 Retained portion Normal and trial of
suction evacuation after
12 days
12 days
trial of
evacuat
4 31 Retained portion Normal and trial of
suction evacuation after
16 days
16 days
trial of
evacuat
5 34 Accreta Cesarean and extirpation The sam
6 29 Increta Cesarean and partial
conservation
8 days
7 26 Increta Cesarean and full
conservation
15 days
8 20 Percreta with
bladder invasion
Cesarean and full
conservation
The sam
9 28 Choriocarcinoma Vaginal delivery 6 weeks
10 23 Choriocarcinoma Vaginal delivery 12 weekchoriocarcinoma (n= 6). Cystoscopy was performed to con-
firm bladder wall invasion for one patient with placenta perc-
reta invading the urinary bladder on MRI. Only 2 patients had
primary postpartum hemorrhage (within 24 h) and the other 8
patients presented after 24 h of delivery (secondary postpar-
tum hemorrhage) (Table 1). The embolization was performed
on emergency bases for 3 patients; two presented after suction
evacuation of retained placenta, and the third one who under-
went placenta accreta extirpation. These procedures were per-
formed with anesthetist and obstetrician supervision. For
nonemergent secondary hemorrhage, the decision to perform
embolization was made on the basis of active continuing hem-
orrhage despite appropriate medical and obstetric treatment.
All patients received prophylactic antibiotics (amoxicillin
clavulanate and metronidazole) just before embolization and
continued for 5–7 days after embolization. Informed consent
was obtained before the procedure.
2.1. Embolization procedure
Pelvic angiography was performed under local anesthesia
through the right common femoral artery approach using a
4–5 F vascular sheath (Cordis Corporation, Europa N.V.,
the Netherlands). Cobra catheter (Optitorque, Terumo corpo-
ration, Tokyo, Japan or Imager, Boston scientific, USA) was
used to catheterize the uterine artery, beginning with the left
side then the right side by looping the catheter in the
abdominal aorta. Microcatheters (2.7/2.9 F Progreat,
Terumo, Tokyo, Japan) were used coaxially when the Cobra
catheter could not be advanced into the distal uterine artery
(beyond the cervico-vaginal artery) or when embolization of
another small pelvic artery was required e.g. vesical branch.
PVA particles 500–700 lm-followed by 700–1000 particles
(Contour; Boston Scientific) were used in all women. NBCA/
Lipiodol mixture and steel coils were used in 2 patients with
choriocarcinoma to occlude large arterio-venous fistulas.ing and methods of embolization.
etween
and UAE
Embolized arteries Embolizing
materials
Bilateral uterine PVA
Bilateral uterine PVA
(just after
ion)
Bilateral uterine PVA
(just after
ion)
Bilateral uterine PVA
e day Bilateral uterine PVA
after Bilateral uterine PVA
after Bilateral uterine PVA
e day Bilateral uterine, bilateral inferior vesical
and left internal pudendal
PVA
Bilateral uterine, left inferior vesical, left
inferior gluteal right internal pudendal
PVA,
NBCA, and
coils
s Bilateral uterine, left inferior vesical,
right inferior vesical, right internal
pudendal
PVA,
NBCA, and
coil
Placental hemorrhage endovascular management 1027Postembolization control angiography was performed to assess
the degree of devascularization of the pathological vessels.
2.1.1. Follow-up
During hospital stay, all patients underwent close follow-up
with clinical examination, serum (B-HCG) measurement, and
pelvic ultrasonography. Clinical success was defined as control
of bleeding without repeating embolization or surgical inter-
vention. Hospital stay ranged from 24 h to two weeks. After
discharge they continued follow-up at home through repeated
visits to the obstetric clinic. MRI was performed once or twice
during the follow-up period for patients with placenta percreta
and choriocarcinoma. The follow-up period ranged from 6 to
30 months (mean: 8 months ± 5).
3. Results
All patients were multiparas and their average gravidity was 2.
The mean hemoglobin level before embolization was 6 g/dL
(range: 4.5–8 g/dL). Severe coagulation disorders were present
in one patient. Blood transfusion (mean number of blood
units: 4; range: 3–9 units) was required for 5 patients before
embolization. The time from delivery to embolization ranged
from few hours to 12 weeks (Table 1). On angiography, all
patients showed blush of hypervascular uterus with or without
the placenta inside. Arterio-venous shunt was detected in asso-
ciation with choriocarcinoma and placenta percreta (n= 3).
Bilateral uterine artery embolization was sufficient to devascu-
larize the abnormal hypervascular blush in 7 patients (Fig. 1).
In 3 patients (placenta percreta or choriocarcinoma), addi-
tional arteries were found to participate in uteroplacental per-
fusion (Figs. 2 and 3). These arteries were the right inferior
vesical artery (n= 2), the left inferior vesical artery (n= 3),
the right internal pudendal artery (n= 2), left internal puden-
dal (n= 1), and left inferior gluteal artery (n= 1). In allFig. 1 Twenty-three year old woman presented with PPH due to r
uterus and placenta. (b) Selective catheterization of the left uterine arte
of the left uterine artery. Right IIA (d), and selective uterine artery (e)
uterine artery.patients, the embolization was technically successful in achiev-
ing stasis of the uterine arteries. Postembolization pelvic angio-
gram showed total devascularization of the pathological
arteries in 7(70%) patients, and subtotal devascularization in
3(30%) patients (with placenta percreta and choriocarcinoma).
Pelvic embolization controlled the bleeding for all patients
and none of our patients required repeated embolization or
hysterectomy (the clinical success is 100%). All the 3 hemody-
namically unstable patients became stable after embolization.
Only one patient needed blood transfusion after the procedure
to correct anemia of previous blood loss. Also the coagulation
disorder that was noted in one patient improved markedly
after embolization. None of our patients developed significant
rebleeding; however, 2 patients had drops of altered blood 2–
3 days after embolization. Also, the patient with placenta perc-
reta continued intermittent minimal hematuria for 4 days after
embolization. Pieces of placenta tissue were spontaneously
passed vaginally after uterine artery embolization in all
patients. Patients with retained small placental parts (retained
placenta, accreta and increta, n= 6) showed complete placen-
tal resorption in a mean time of 4 weeks (range 1–6 weeks). In
patient with placenta percreta, the uterus became totally empty
of placenta after 21 weeks. Low grade fever was noted in 4
(44%) patients after the procedure. No general or local com-
plications were noticed and no mortality occurred during the
period of follow-up. Two patients became pregnant 16 and
20 months consequently after uterine artery embolization.
Both of them had an uneventful intrauterine full term
pregnancy and both had Cesarean section delivery.4. Discussion
Retained placenta was reported as the most common cause of
secondary PPH (14). In such cases, suction evacuation and
curettage are often successful in stopping the hemorrhage,etained placenta. (a) Left IIA angiogram showing hypervascular
ry with a microcatheter. (c) Control angiogram after embolization
angiogram. (f) Control angiogram after embolization of the right
Fig. 2 Twenty year old woman presented with PPH due to placenta percreta invading the urinary bladder. (a) Sagittal MRI of the pelvis
showing hypervascular placenta infiltrating the anterior uterine wall. (b) Right IIA angiogram showing hypervascular uterus and placenta
with arterio-venous shunt. Selective uterine (b), and inferior vesical (c) catheterization. (e) Post-embolization angiogram of the right IIA.
Pre-embolization (f) and postembolization (g) angiography of the left IIA. (h) Sagittal MRI 3 months after embolization showing marked
regression of the placenta. The placenta was expelled completely after 21 weeks.
Fig. 3 Twenty-three year old woman presented with PPH due to choriocarcinoma. (a and b) Sagittal MRI showing uterine and
extrauterine extension of the choriocarcinoma. Selective angiography of the left inferior vesical (c), and uterine arteries (d), showing
extensive arterior-venous shunt. (e) Postembolization angiography of the left uterine artery. (f) Catheterization of the right uterine (f), and
pudendal-vesical common trunk (g). (h) Control angiography of the right IIA showing NBCA filling the pathological vessels.
1028 H.M.A. Seif, L.M.R. Khalafbut it may also increase placental bleeding (15). This scenario
occurred in 2 of our patients, who bled profusely after trial of
evacuation of retained placental portion. Because, all cases
with retained placenta treated for spontaneous or iatrogenic
PPH, responded well to UAE with complete expulsion of the
placental remnants, it is better to avoid attempt of suction
evacuation of the retained placenta.Three subtypes of PA are described: the first (80%) is super-
ficial attachment to the myometrium (accreta vera); the second
(15%) is subtotal invasion into the myometrium (increta); and
the third (5%) is total invasion into the myometrium and ser-
osa with or without pelvic organ invasion (percreta) (16).
Women with placenta accreta, increta or percreta are at high
risk of life-threatening hemorrhage with reported maternal
Placental hemorrhage endovascular management 1029mortality rate up to 7% in women with placenta percreta (17).
For prenatal diagnosis, the presence of risk factors for pla-
centa accreta should be sought for. Prior Cesarean section
and placenta previa are the two most important risk factors
(18,19). Other risk factors are multiparity (>6 pregnancies),
elevated maternal serum alphafetoprotein and maternal age
more than 35 years (20). Doing ultrasonography, one could
find irregular placental lacunae, thinning of myometrium over-
lying the placenta, loss of retroplacental non-lucent line,
increased vascularity of the uterine serosa-bladder interface,
protrusion of the placenta into the bladder, and turbulent blood
flow through the lacunae on Doppler ultrasonography (21,22).
MRI is the gold standard imaging modality for placenta accreta
especially in case of placental invasion of pelvic organs. Unfor-
tunately, most cases are identified during delivery when forcible
attempts at manual removal of the placenta are unsuccessful
and severe PPH ensues. The most common complications to
PPH and massive blood transfusion are DIC, acute renal fail-
ure, infectious morbidities, and ARDS (23).
Treatment of placenta accreta is by either extirpative or
conservative approaches. Extirpative approach which is the
manual removal of the placenta (24), may result in severe hem-
orrhage that may require emergency hysterectomy (17). In
addition, extirpative management results in a substantial
increase in morbidity due to subsequent endometritis, ureteral
and bladder damage and fistula formation (17). The conserva-
tive approach is either ‘‘cesarean hysterectomy” during which
the abnormal placenta is removed along with the uterus or
‘‘full conservation” which is leaving both the uterus and the
abnormal placenta inside (24,25). Full conservative approach
reduced hysterectomy rate from 84% to 15% (24), but it car-
ries risk of PPH (2,26). Many reports have described the suc-
cessful use of pelvic embolization in cases of postpartum
bleeding in women with placenta accreta or percreta (27,10).
Sentilhes et al. in 2010 (28) reviewed conservative management
in 167 cases of placenta accreta/percreta and found failure rate
of 22% which required hysterectomy. Two of our patients
were treated successfully by full conservative management
without need of further hysterectomy. Prophylactic emboliza-
tion of internal iliac or uterine arteries was suggested previ-
ously (29). However, in our study and in a study performed
by Phillipe et al. (10), no cases of technical failure were
observed and emergency pelvic embolization was feasible in
all patients. Furthermore, Timmermans et al. (4) in their retro-
spective review of placenta accreta found that secondary PPH
occurs in only 22–23% of patients treated with conservative
management. Therefore, it is not wise to do prophylactic
embolization and UAE is spared to treat PPH. Pelvic
embolization of placental abnormalities should not be limited
to the uterine arteries only but comprehensive analysis of the
pelvic vasculature must be made also (30). Three of our
patients who had extrauterine extension of the placenta (pla-
centa percreta and choriocarcinoma) needed embolization of
additional branches other than the uterine arteries. The
reported success rate of UAE in cases of PPH ranged from
61% to 100% (31,32), and the global success rate reached
90% (33,34). Previous series reported a lower pelvic arterial
embolization success rate in cases of placenta accreta/percreta,
which ranged between 60% and 83% (35). On the contrary,
other authors reported higher success rate (2,24,36). We have
100% clinical success in this study which may be due to the
use of PVA particles that give longer time of occlusioncompared with Gelfoam used in most studies; embolization
of all accessible supplying branches (uterine and extrauterine
pelvic arteries), and the use of long time of broad spectrum
antibiotic presenting sepsis. Many authors believe that Gel-
foam is the embolizing materials of choice in treatment of
PPH, because it dissolves early preventing permanent vessel
occlusion (37,38). Recently, the use of potentially non-
absorbable particles such as PVA or embosphere particles
has been recommended for treatment of placenta accreta
(39,35). In this study we used potentially non-absorbable par-
ticles in all patients due to the following reasons. Firstly,
embolization of placenta accreta/percreta may need longer
time of arterial occlusion as placental expulsion may occur
after months, and Gelfoam may recanalize before complete
regression or expulsion causing rehemorrhage. This scenario
was described by Minna et al. (40) who presented a case report
of a woman bled massively 7 weeks after cesarean section and
gelfoam embolization, and hysterectomy was the end result.
Secondly, in a review of cases developed uterine necrosis
(41), no definite relationship between the type of embolizing
materials and necrosis could be identified. Uterine necrosis
together with other ischemic complications such as urologic
complications, ovarian failure and definitive amenorrhea have
been described related to the small sized particles, rather than
the type of the embolic materials (absorbable or inabsorbable)
(27,42,39,43). Lastly, there are a lot of publications reporting
normal pregnancy after embolization of uterine arteries with
non-absorbable particles for treatment of fibroids and PPH.
This also happened in two of our patients who became preg-
nant after embolization.
Most of our patients had free uterus of placenta within
4 weeks after embolization, except the patient with placenta
percreta invading the bladder who needed 21 weeks for placen-
tal expulsion. The previously reported resorption interval ran-
ged from 4 to 60 weeks (28). Placenta percreta invading
urinary bladder is a challenging condition that may cause
hematuria, bladder laceration, urinary fistula, and ureteral
injury (44). Noriyuki et al. (45) published a case report of pla-
centa percreta invading the urinary bladder causing hematuria.
They treated the patient by cesarian hysterectomy, leaving a
part of the anterior lower uterine segment adherent to the pos-
terior bladder wall together with the invading portion of the
placenta to absorb spontaneously. This patient developed
hemorrhage, and vesicovaginal fistula, and partial cystectomy
was performed. After 7 months the patient suddenly died
because of sepsis. Lam et al. (46) reported a case of successful
conservative management of placenta previa accreta. The
patient resumed menstruation 5 months after delivery. In
2009, Abdoulaye et al. (39) published a case report of placenta
percreta invading the urinary bladder. She was treated conser-
vatively with adjuvant prophylactic UAE using calibrated par-
ticles (Embosphe`re) in complement with absorbable gelatin.
The placental portion invading the bladder wall was treated
with cystoscopic resection, and peritumoral coagulation. We
treated a patient with placenta percreta invading the urinary
bladder fully conservative. Bilateral uterine and inferior vesical
arteries were embolized with PVA particles. The placenta was
expelled after 21 weeks without surgical or cystoscopic
intervention.
Patients with non-metastatic (stage I) and low-risk meta-
static (stages II and III) gestational trophoblastic neoplasm
(GTN) can be treated with single-agent chemotherapy, with
1030 H.M.A. Seif, L.M.R. Khalafresulting survival rates approaching 100% (47). Aggressive
treatment such as multiagent chemotherapy, adjuvant radia-
tion or surgery has reserved to cure high risk metastatic disease
with cure rates of 80–90% (47). GTN is highly vascular and is
usually associated with uterine vascular malformations. Over-
all, 1–2% of these uterine vascular malformations cause vagi-
nal or intraperitoneal hemorrhage (48). Since the majority of
such vascular malformations are supplied predominantly by
the uterine arteries, pelvic embolization has been successfully
used to treat GTN-associated genital bleeding (49,11,50).
Keepanasseril et al. (51) studied 8 women with GTN presented
with massive hemorrhage and the embolization was successful
in 85.7% of the patients. In our two patients presented with
uterine bleeding due to choriocarcinoma, it was difficult to
achieve complete devascularization due to multiple arterial
supply and extensive arterio-venous shunt. After embolization
the patient stopped bleeding and was cured completely with
chemotherapy treatment without need for hysterectomy.
The most commonly reported adverse effect of UAE is
fever noted in 4(44%) of our patients. Fever may represent
an inflammatory response to tissue necrosis especially with
the use of prophylactic broad-spectrum antibiotic therapy,
and rarely as a result of sepsis or endometritis. Other rare com-
plications include septic shock, peritonitis, uterine necrosis,
injury to the adjacent organs, acute pulmonary edema, acute
renal failure, deep vein thrombophlebitis, pulmonary embo-
lism, bladder wall necrosis, vesicovaginal fistula, labial or vagi-
nal necrosis, and partial small bowel necrosis (52–55). Despite
resulting in an incidence of uterine synechiae of 11.7%, UAE
did not seem to compromise subsequent fertility among a ser-
ies of 68 women (56). Also in this study we reported two full
term pregnancies after UAE.
In conclusion, whatever the placental disease, pelvic
embolization with long-lasting embolizing agent is very effec-
tive and safe treatment for associated postpartum hemorrhage.
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